Novartis Phase III PREVENT Study: IL-17A Monoantigen Cosentyx Can Persist-Relief Axial Spinal Arthritis
-
Last Update: 2020-06-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Novartis announced the results of a phase III PREVENT trial that further demonstrated that its resistance to IL-17A monoantigen Cosentyx (secukinumab) can provide lasting benefits for patients with apron arthritis (axSpA)studies found that non-radioactive axial spinal arthritis (nr-axSpA) patients treated with Cosentyx 150 mg showed significant and sustained improvement in symptoms at 52 weeks"Middle-axial spinal arthritis can seriously affect a patient's quality of life and ability to live, " said DrJ?rgen Braun, a researcher at the Cosentyx clinical trialPREVENT demonstrates the effectiveness and safety of Cosentyx in non-radioactive patients with axial spinal arthritisCosentyx is the first in-the-same (IL)-17A inhibitor for patients with nr-axSpa in Europe and has previously been supported by extensive data in clinical trials of patients with moderate to severe plaque psoriasis (PsO), psoriasis arthritis (PsA) and strong spinal itisis (AS)April 2020, Novartis obtained approval from the European Commission for Cosentyx for nr-axSpA treatmentNovartis has referred Cosentyx to the U.SFood and Drug Administration (FDA) and the Japan Pharmaceutical and Medical Devices Agency (PMDA) for review to treat nr-axSpA adultsCosentyx is the first and only all-human source IL-17A monoantigen, an important cytokine involved in inflammation of PsO, PsA and AS diseases
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
